Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific Officer NEW HAVEN, Conn., January 5, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that it...
Intarcia Secures Second Close of the Series EE Equity Financing for an Additional $206M; As Part of the Financing and a New Strategic Initiative, Intarcia Now Aims Its Medici Technology Towards Preventing HIV ? The Bill & Melinda Gates Foundation is committing up...
AiCure’s Artificial Intelligence Platform Wins 2016 Scrip Award Using artificial intelligence to optimize patient behavior NEW YORK, Dec. 1, 2016 /PRNewswire/ — AiCure, which uses artificial intelligence (AI) on mobile devices to visually confirm medication ingestion,...
Intarcia Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of ITCA 650 in Type 2 Diabetes The NDA submission reflects more than 10 years of innovation and clinical development of ITCA 650 to respond to pressing unmet needs in type 2 diabetes. ITCA...
UAB Medicine Selects Kyruus for Patient-Provider Matching and Provider Data Management on Nov 14, 2016 12:54:00 PM BOSTON, MA – Kyruus, a leader in provider search and scheduling solutions for health systems, announced today that UAB Medicine, one of the top four...
CRISPR Therapeutics Announces Pricing of Initial Public Offering BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) — CRISPR Therapeutics AG (Nasdaq:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing...
Recent Comments